Safety of Viracept 625 mg in Pregnant Women with HIV

Phase 4, open-label, single-arm trial of nelfinavir in human immunodeficiency virus infection (HIV), sponsored by Pfizer. Primary endpoint: Presence or absence of at least one adverse event related to or possibly related to nelfinavir of Grade 2 or greater severity in the gastrointestinal or hepatic category at 32 weeks. Started Mar 2006; status: completed.